GEN Exclusives

More »

GEN News Highlights

More »
Jan 9, 2012

Akebia Spins out Aerpio to Develop Tie-2 Activators and HIF-1a Stabilizers

  • Akebia Therapeutics has spun out a new company, Aerpio Therapeutics, to continue the development of its small molecule Tie-2 activator and HIF-1α stabilizer programs for multiple diseases. The spin-out’s pipeline includes lead program, AKB-9778, a Tie-2 activator in development for the treatment of diabetic macular edema (DME), which is expected to start in a Phase IIa trial during the first half of 2012. AKB-9778 is designed to inhibit human protein tyrosine phosphatase β, a negative regulator of the Tie-2 receptor, and prevent vascular leak and abnormal blood vessel growth associated with diabetic eye disease. A first-in-man study with the candidate was initiated in November 2011.

    Aerpio’s second clinical candidate, AKB-4924, is an HIF-1α stabilizer currently in late preclinical development for the treatment of inflammatory bowel disease (IBD). An IND submission is projected for late 2012. AKB-4924 is designed to stabilize HIF-1α by inhibiting HIF prolyl hydroxylases, and in particular PHD-2.

    Akebia’s own lead candidate, AKB-6548, is an orally available hypoxia-inducible factor-prolyl hydroxylase (HIF-PF) inhibitor in development for the treatment of anemia. The drug is designed to increase natural production of erythropoietin, and cause a controlled, gradual rise in hemoglobin levels in anemia patients. A Phase IIa dose-ranging trial evaluating AKB-6548 in stage 3 and 4 chronic kidney disease patients was initiated in June 2011.

    Akebia separately confirmed drawing down a $4.1 million tranche of a previously announced $22 million Series B financing to support completion of the Phase II AKB-6548 and progress its search for the optimum partner to move into pivotal Phase III studies. 


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Should the CDC Director Resign?

Do you think the CDC chief should resign?